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ABSTRACT
Shedding of ADAM10 substrates, like TNFa, MICA or CD30, is reported to affect both anti-tumor immune
response and antibody-drug-conjugate (ADC)-based immunotherapy. Soluble forms of these molecules
and ADAM10 can be carried and spread in the microenvironment by exosomes released by tumor cells.
We reported new ADAM10 inhibitors able to prevent MICA shedding in Hodgkin lymphoma (HL), leading
to recognition of HL cells by cytotoxic lymphocytes.
In this paper, we show that the mature bioactive form of ADAM10 is released in exosome-like vesicles
(ExoV) by HL cells and lymph node mesenchymal stromal cells (MSC). We demonstrate that ADAM10
inhibitors are released in ExoV by MSC or HL cells, endocytosed by bystander cells and localized in the
endolysosomal compartment in HL MSC. ExoV released by HL cells can enhance MICA shedding by MSC,
while ExoV from MSC induce TNFa or CD30 shedding by HL cells. Of note, ADAM10 sheddase activity
carried by ExoV is prevented with the ADAM10 inhibitors LT4 and CAM29, pretreating either the ExoV-
producing or the ExoV-receiving cells. In particular, both inhibitors reduce CD30 shedding maintaining the
anti-tumor effects of the ADC Brentuximab-Vedotin or the anti-CD30 Iratumumab on HL cells.
Thus, spreading of ADAM10 activity due to ExoV can result in the release of cytokines, like TNFa, a
lymphoma growth factor, or soluble molecules, like sMICA or sCD30, that potentially interfere with host
immune surveillance or immunotherapy. ADAM10 blockers can interfere with this process, allowing the
development of anti-lymphoma immune response and/or efficient ADC-based or human antibody-based
immunotherapy.
KEYWORDS
immune escape; immune
stress; alfa-secretase
Introduction
ADAMs (A Disintegrin And Metalloproteinase) family includes
transmembrane proteins with protease activity exerted through a
catalytic metalloproteinase domain on a wide panel of substrates.1,2
When this process targets transmembrane molecules, including
growth factors, cytokines, receptors and their ligands or cell adhe-
sion molecules, it is called ectodomain shedding and leads to the
release of soluble bioactive molecules.1,2 Some of them, such as
tumor necrosis factor (TNF)a, a substrate for ADAM17 and
ADAM10, are involved in the pathogenesis and development of
several cancers.3-6 Moreover, overexpression of ADAM10 or
ADAM17 relates with parameters of tumor progression (size,
grade, metastasis and lymph node involvement).6,7 Thus, ADAMs
have been proposed as both biomarkers and therapeutic targets for
cancer,7,8 while ADAM10 or ADAM17 inhibitors with anti-tumor
effects have been described.9-11
The sheddase activity of ADAMs can also target the so-
called “stress molecules”, like the MHC-class-I related MICA
and MICB, and the UL16 binding proteins (ULBPs), expressed
on cancer cell surface and responsible for inducing an immune
response against tumor cells.12,13 This mechanism has been evi-
denced in chronic lymphocytic leukemia, acute myeloid leuke-
mia, non-Hodgkin and Hodgkin’s lymphomas (HL).14-17 In
particular, we described overexpression of ADAM10 in the
lymph node microenvironment in HL, together with impaired
stimulation of T lymphocytes with anti-tumor activity.18 Like-
wise, CD30 shedding due to ADAM10 activity, has been
reported to decrease the efficiency of targeted lymphoma cell
killing obtained with monoclonal antibodies in vitro and this
effect can be prevented by the use of the inhibitor
GI254023X.19 We also developed inhibitors with high specific-
ity for ADAM10 to enhance efficiency and selectivity of action;
exposure of HL cells to these inhibitors significantly increases
their sensitivity to lymphocyte-mediated killing.20,21
Bioactive ADAM10 can be released in extracellular microve-
sicles (EV, 150–800 nm of size) and exosomes (<150 nm) as
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well, derived either by tumor or by neighboring stromal cells,
which are potentially able to spread the ADAM10 enzymatic
activity in the microenvironment.22,23 Indeed, EV contain mul-
tiple cytoplasmic or membrane molecules derived from the
budding process, including growth factors, cytokines and met-
alloproteases, that can interact with EV recipient cells and
deliver signals promoting tumor invasiveness and metasta-
sis.24,25 Since the process of EV release is particularly active in
proliferating cells, such as cancer cells, it has further been pro-
posed that EV and exosomes can play a role in promoting and
maintaining tumor cell survival. Of note, exosomes have been
described to down-regulate NKG2D expression on natural
killer and T lymphocytes, representing a powerful mechanism
of immune escape.26,27 Thus, it is worth inhibiting ADAM10
enzymatic activity conveyed by the EV exchange between stro-
mal and cancer cells.
In this paper, we show that: i) ADAM10 mature form
is released in exosome-like vesicles (ExoV) by HL cells
and lymph node mesenchymal stromal cells (MSC); ii)
fluorescent ADAM10 inhibitors localize in the endolysoso-
mal compartment in HL MSC, are released in ExoV and
are in turn endocytosed by bystander cells; iii) ADAM10
sheddase activity carried by ExoV is prevented by the spe-
cific inhibitors LT4 and CAM29; iv) further, LT4 and
CAM29 reduce CD30 shedding maintaining Brentuximab-
Vedotin (Btx Ved) and Iratumumab effects in Hodgkin
lymphoma cells.
Results
ADAM10 mature form is released in ExoV by HL cells and
lymph node MSC. ADAM10 evaluated in post nuclear superna-
tants (cells) or in the exosome-like enriched fraction (ExoV) of
HL cells, is mainly present as the mature form of about 68kDa
after prodomain removal. ExoV were also positive for the spe-
cific exosomal marker CD81 and the ADAM10 substrate
MICA/B, the latter detectable in L428 and, to a lesser extent, in
L540 cells (Figure 1A). The low MW band (35k Da) visible in
ExoV was already reported as an ADAM10 cleavage product.28
Transmission electron microscopy (TEM) analysis of L428 or
L540 ExoV (Figure 1B, left panels) revealed the prevalence of
small vesicles ranging from 50 to 150 nm in diameter, while
flow cytometry showed ADAM10 reactivity in L428 ExoV con-
jugated with latex beads (Figure 1B, right panel). ADAM10 was
also detected in MSC and HL cells isolated from the same HL
lymph node (LN) (MSC773 and RS773 cells), as well as in their
ExoV and conditioned medium (CM) (Figure 1C). ADAM10
expression on both MSC and Reed-Sternberg cells has been
detected at the tumor site in HL (Suppl. Fig. 1A–B).18 Likewise,
ADAM10 was detected by western blot (WB) in ExoV purified
from the sera of 6 HL patients (Suppl. Fig. 1C).
An ADAM10 soluble form (sADAM10) is apparently pres-
ent in the CM of RS773 cells as a band of MW intermediate
between mature ADAM10 and the precursor form (Figure 1C).
The evidence that ADAM10, besides initiating intramembrane
Figure 1. ADAM10 mature form in ExoV is released by MSC and HL cells. Panel A: Post nuclear supernatants (cells) or exosome-like vesicles (ExoV), prepared from the condi-
tioned medium (CM) of L428, L540 or KMH2 HL cells (107) by differential centrifugation, were lysed, subjected to western blot, probed with the anti-ADAM10 antiserum or
the anti-CD81 or the anti-MICA/B mAb, followed by HRP-labeled antibodies and developed with ECL. MW markers (kDa) are indicated on the left. Panel B: Transmission
electron microscopy (TEM) analysis of L428 or L540 cell ExoV (left panels). Flow cytometry analysis (right panel) of L428 ExoV conjugated overnight with latex beads
(4 mm) and stained with the anti-ADAM10 antibody followed by an APC-conjugated antiserum (grey histogram) or with the APC-antiserum alone (white histogram). Panel
C: ExoV and CM from MSC773 or RS773 HL cells were subjected to western blot for ADAM10 as in panel A. Panel D: TEM images of stromal ExoV from MSC773. Panel E:
MSC773 cells were silenced with specific (A10) or non-targeting (NT) siRNA pool. Cell lysates, or lysates from ExoV purified from NT or A10 MSC supernatants, were sub-
jected to western blot as in panel A and probed with anti-ADAM10 mAb or mAbs against the exosomal markers CD81 and CD63, as in panel A, or the anti-b-actin mAb.
MW markers (kDa) are indicated on the left.
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proteolysis of several substrates, is itself subject to a proteolytic
cascade is growing. MSC ExoV were also analyzed upon TEM
visualization, as shown in Figure 1D (average dimension: 60%
50–100 nm, 40% 100–200 nm). ADAM10 silencing in MSC773
cells determined a decrease both in cytoplasmic and in ExoV
content, confirming the role of stromal ExoV as ADAM10
extracellular carriers. On the other hand, the exosomal markers
CD81 and CD63 are unaffected by ADAM10 silencing
(Figure 1E). Moreover, ADAM10 silencing in MSC773 resulted
in reduced ADAM10 surface expression (Suppl. Fig. 2A) and
sMICA shedding (Suppl. Fig. 2B).
ADAM10 inhibitors localize in the endolysosomal compart-
ment in HL MSC. As shown in Figure 2A (left blot), the analysis
of subcellular fractions isolated from MSC16412 showed that
the precursor and the mature form of ADAM10 is mainly local-
ized in the endolysosomal compartment (lysosome, L and
endosome, E enriched fractions), identified by LAMP-1 and
cathepsin-D, or by EEA1, respectively with a detectable amount
in the membrane (M) fraction, but not in the cytosol (SN). The
presence of EEA1 in the SN due to dissociation from early
endosomes (EE) has been described.29 To determine the subcel-
lular distribution of the ADAM10 inhibitors that we reported
to be active on HL cells,20,21 we performed a series of experi-
ments using the previously described LT4, the newly synthe-
sized CAM29, both showing a IC50 selective for ADAM10
(Supplemental Data and Suppl.Table 1), or CAM29 conjugated
with cyanine 5.5 (Cy5.5, CAM36) or with fluorescein isothiocy-
anate (FITC, CAM50).30 First, upon exposure to LT4
(Figure 2A), and CAM29 (not shown), ADAM10 time-depen-
dent compartmentalization in endolysosomes increased in
MSC16412, possibly interfering with ADAM10 stability due to
retention in the degradative pathway while decreasing
Figure 2. ADAM10 inhibitors localize in the endolysosomal compartment in HL MSC. Panel A: Subcellular fractions (L, E, M, SN, as indicated in the text) were obtained from
107 MSC16412 as described in Materials and Methods, either untreated (left blot) or upon 48 h exposure to LT4 (right blot) and Western Blot was performed with the indi-
cated antibodies: anti-ADAM10 ectodomain, anti-LAMP-1, anti-cathepsin D, anti-Rab7 (late endosomes, lysosomes) or anti-EEA1 (endosomes) mAbs, as indicated, followed
by secondary anti-mouse HRP-labeled antibodies and ECL development. Panel B: MSC16412 were incubated with CAM29 (from10 mM to 1 mM, light grey histograms)
20 min at RT, washed and stained with the anti-ADAM10 mAb followed by APC-GAM (dark grey histograms) or APC GAM alone (white histograms), washed and run on a
FACS. Results are shown as Log far red fluorescence intensity (a.u.) vs number of cells. One representative experiment out of four is shown. Panel C: MSC16412 and MSC
773 were treated with 10 mM LT4 or CAM29 o.n. at 37C, then RNA was extracted and real-time RT-PCR for ADAM10 performed as described in Materials and Methods.
Results are expressed as relative mRNA expression values. Panel D: MSC16412 seeded on 0.2 mm thin round glass slides were incubated for 24 h with Rab5GFP (2 mL) or
for 1 h with LysoTracker Red (50 nM); after washes, slides were stained with CAM36 or CAM50 (5 mM for 60 min at RT). Panel E: MSC16412 seeded on glass slides were
treated with to 10 mM nocodazole (NZ) for 1 h at 37C, prior to exposure to CAM36. Samples were washed and analyzed by FV500 FluoView Confocal Laser Scanning
Microscope System (Olympus), with PlanApo 40x NA1.00 (E) or 60x NA1.40 (D) oil objectives; the data were analyzed with FluoView 4.3b computer program. Images were
taken in sequence mode to avoid cross-talk among fluorochromes and shown in pseudocolor (green or red) or bright field, as indicated.
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membrane localization (Figure 2A, right blot). Second, expo-
sure of MSC16412 (Figure 2B) or MSC773 (not shown) to
CAM29 led to a reduction of surface reactivity of the anti-
ADAM10 mAb and this interference was dose-dependent
(Figure 2B), thus supporting that the inhibitor induces a con-
formational change and/or a subcellular redistribution of
ADAM10 that becomes unavailable for antibody binding. Con-
versely, treatment with ADAM10 inhibitors did not alter signif-
icantly ADAM10 mRNA levels in either MSC (Figure 2C) or
L540 and L428 (not shown).
Then, MSC16412 (Figure 2D) or MSC773 (not shown) were
pre-incubated with either Rab5-GFP, specific for early endo-
somes (EE), or LysoTracker to identify lysosomes (L) and late
endosomes (LE), followed by staining with CAM36, and ana-
lyzed by confocal microscopy. First, both membrane and intra-
cellular vesicular distribution of CAM36 can be observed, with
limited co-localization with Rab5-GFP, mainly in sub-mem-
brane areas or, at a lesser extent, in perinuclear microvesicles
(Figure 2D, upper and middle panels, yellow points in the
merged images). On the other hand, MSC16412 (Figure 2D) or
MSC773 (not shown) pre-incubated with LysoTracker Red and
then stained with CAM50, displayed an intense co-localization
of the inhibitor in intracellular microvesicles (Figure 2D, lower
panels, yellow points in the merge images) that can be defined
as the endolysosomal compartment. When MSC16412 were
pretreated with nocodazole (NZ), that interferes with microtu-
bule polymerization and endocytosis, a reduction in CAM36
uptake was observed (Figure 2E). These data strongly suggest
that the ADAM10 inhibitors bind to the enzyme and mostly
share its localization, both at the cell membrane and in the sub-
cellular trafficking compartments.
ADAM10 inhibitors are released in ExoV and endocytosed by
bystander cells. To further evaluate the localization of ADAM10
inhibitors, we performed transmission electron microscopy
(TEM) on MSC16412 exposed for 24 h to the gold-conjugated
CAM29 (CAM49) compound.30 As shown in Figure 3A,
CAM49 was detectable in microvesicles, one appearing as a
blebbing structure (Figure 3A, quadrant in a enlarged in b),
indicative of membrane internalization by endocytosis.31 Thus,
we set up a series of experiments using ExoV purified from
conditioned medium of MSC or HL cell lines.
ExoV obtained from MSC16412 (Figure 3 and 4) or
MSC773 (not shown), either untreated or exposed to CAM36
for 24 h, were first conjugated with latex beads and analyzed by
flow cytometry (Figure 4). ExoV derived from MSC16412
exposed to CAM36 (Cy5.5) were detected as far-red fluorescent
events, compared to ExoV from untreated MSC16412
(Figure 4A, upper quadrant, dark grey vs light grey histo-
grams); moreover, ExoV from untreated MSC16412 expressed
ADAM10, as evidenced by the specific mAb (Figure 4A, lower
quadrant, dark grey histogram), thus indicating that ADAM10
inhibitors localize in ExoV where ADAM10 is detectable as
well. In other experiments, MSC16412-derived ExoV were
added (15 mg/105cells) for 24 h to L428 cells: of note, ExoV
from CAM36-treated MSC16412 were endocytosed by L428
cells, as detectable by flow cytometry (Figure 4B, upper quad-
rant, black vs light grey histograms) and by confocal micros-
copy (Figure 3B); in particular, areas of co-localization (yellow
dots) of ExoV-CAM36 (red) with Rab5-GFP (green) are
present in L428 cells. Likewise, ExoV from CAM36-treated
L428 cells were endocytosed by MSC16412 (15 mg/105cells) as
evidenced by flow cytometry (Figure 4B, lower quadrant, black
vs light grey histograms) and by confocal microscopy
(Figure 3C and D). Figure 3 C shows that ExoV-CAM36 (red)
are partially co-localized (yellow dots) with Rab5-GFP (green)
that identifies early endosomes; moreover, in Figure 3D, coloc-
alization (yellow) with the lysosomal compartment marker
LysoTracker (green) is depicted. The dark grey histogram in
Figure 4B, upper quadrant, indicates L428 cells incubated with
ExoV from MSC16412 exposed to the unrelated Cy5.5 com-
pound ST178.
ADAM10 in ExoV from MSC and HL cells is active and
inhibited by LT4 or CAM29. To evaluate the ADAM10 activity
carried by ExoV and verify the blocking by specific inhibitors,
we used ExoV purified from L428 or L540 cells or MSC773,
untreated or cultured in the presence of LT4 or CAM29
(10 mM) for 48 h. MICA was chosen as substrate for ADAM10
in MSC because these cells do not express CD30 (Figure 5A,B)
and do not produce TNFa.32 CD30 (see below) and TNFa
were chosen for HL cell lines as they are expressed by these cells
(Figure 5A,B) and are substrates for ADAM10 and/or
ADAM17.33,34
As shown in Figure 4C, ExoV from L428 and, to a lesser
extent, those released by L540 cells, were able to increase the
shedding of sMICA by MSC773 cells and this effect was dose-
dependent. Of note, ExoV released by L428 cells pretreated
with the ADAM10 inhibitor LT4 did not enhance sMICA shed-
ding by MSC773 (Figure 4D). In turn, ExoV from untreated
MSC773 could increase the shedding of TNFa by L428 cells
(Figure 4E, left and right graphs, central white columns). In
this case, ExoV from LT4 treated MSC were also effective
(Figure 4E, left graph, right white column). On the other hand,
ExoV from MSC773 pretreated with CAM29 were less effective
in increasing TNFa release (Figure 4E right graph, right white
and grey columns); likewise, the effect of MSC773-derived
ExoV on TNFa shedding was lower when L428 cells were pre-
treated with CAM29 (Figure 4E, right panel, central and right
grey columns).
ADAM10 inhibitors reduce the shedding and maintain the
expression of CD30 on HL cells increasing the biological effect of
the ADC Btx Ved and the humanized anti-CD30 Iratumumab.
As CD30 is a reported substrate for ADAM10 and is also a tar-
get for immunotherapy,19,32,34,35 we first analyzed the effect of
ExoV on CD30 shedding from L540 and L428 cells and the
possible counteracting action of ADAM10 inhibitors. In
Figure 5A and B expression of CD30 on L428 cells and their
ExoV is shown, compared to MSC16412 and related ExoV that
are CD30 negative. Figure 5C shows that ExoV from
MSC16412 were able to increase the shedding of sCD30 by
L428 cells. In turn, ExoV released by MSC16412 pretreated
with the ADAM10 inhibitor LT4 or CAM29 (both at 10 mM
concentration; Figure 5 C left and right graph, respectively)
were less effective in enhancing sCD30 shedding by L428.
When L428 cells were treated with LT4 before exposure to
MSC-derived ExoV, the increase in sCD30 shedding was less
evident (Figure 5C, left graph). Noteworthy, ExoV obtained
from L428 cells added to MSC16412 resulted in a detectable,
dose-dependent sCD30 shedding (Figure 5D), conceivably of
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Figure 3. ADAM10 inhibitors are released in ExoV and endocytosed by bystander cells. Panel A: a) TEM image of MSC16412 showing the nucleus (n), the endo-
plasmic reticulum (er), vacuoles (v) and lysosomes (l) and, close to the cytoplasmic membrane, microvesicles (mv) with gold aggregates. b) Magnification of
the quadrant in a). Bar D 500 nm. Panel B: L428 cells, incubated with Rab5-GFP 24 h before addition of ExoV obtained from CAM36-treated MSC16412,
analyzed by confocal microscopy after 4 h; arrows indicate areas of co-localization (yellow dots) of ExoV-CAM36 (red) with Rab5-GFP (green). Panel C and D:
MSC16412 seeded on 0.2 mm thin round glass slides were incubated for 24 h with Rab5-GFP (2 mL, panel C) or for 1 h with LysoTracker DND99 (50 nM,
panel D) together with Syto16, 1 mM; then ExoV obtained from CAM36-treated L428 were added for 4 h and samples analyzed by confocal microscopy
(as indicated). Samples were observed with PlanApo 40x NA1.00 (B,C, D upper) or 60x NA1.40 (D lower, enlargement of D upper) oil objectives and data ana-
lyzed with FluoView 4.3b computer program (Olympus). Results are shown as bright field or pseudocolor images. Lower row in panel D: enlargement of the
square in the upper row. Arrows: colocalization areas.
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Figure 4. ADAM10 inhibitors are released in ExoV and endocytosed by bystander cells: effects on sMICA and TNFa shedding. Panel A: Upper quadrant: ExoV, from
MSC16412 exposed to CAM36 (Cy5.5) for 24 h were conjugated with latex beads (dark grey histograms) compared with beads-conjugated ExoV from untreated
MSC16412 (light grey histogram as in upper quadrant; white: beads alone). Lower quadrant: ExoV, obtained from untreated MSC16412 were conjugated with
latex beads (light grey histograms) and stained with anti-ADAM10 mAb followed by APC-GAM (dark grey histogram; white: latex beads plus APC-GAM). Panel
B: Upper quadrant: L428 cells added of ExoV obtained from untreated (light grey histogram) or CAM36-treated MSC16412 (black histogram; white histogram:
L428 without ExoV) for 24 h. Dark grey histograms: L428 cells incubated with ExoV (15 mg/106cells) from MSC16412 exposed to the unrelated Cy5.5 compound
ST178. Lower quadrant: ExoV (15 mg/106cells) from untreated (light grey histogram) or CAM36-treated (black histogram) L428 cells were added for 24 h to
MSC16412 (white histogram: MSC16412 without ExoV). Panels A and B: samples were run on a CyAn ADP Analyzer and results, representative of four experi-
ments, are expressed as Log far red fluorescence intensity (a.u.) vs number of cells. Panel C: sMICA (pg/ml/105 cells) in the SN of MSC773 cultured for 48 h
without or with ExoV (15, 30 or 60 mg for 48 h) from L428 (black circles) or L540 (white circles) HL cell lines. Panel D: sMICA (pg/ml/105 cells) in the SN of
MSC773 before or after the addition of ExoV (10 or 30 mg for 48 h) from L428 untreated or pretreated with 10 mM LT4, as indicated. ExoV30 mg RPMI: sMICA
content in the SN of ExoV cultured alone. Panel E: TNFa content (pg/ml/105 cells) in the SN of L428 cells cultured for 48 h without or with ExoV (30 mg)
released by MSC773, untreated or pretreated with 10 mM LT4 (left histograms) or 10 mM CAM29 (right histograms). Some samples were prepared using L428
cells exposed for 24 h to either 10 mM LT4 (left histograms) or 10 mM CAM29 (right histograms), before addition of MSC-derived ExoV. p< 0.05, p<0.01,
p<0.001 vs Nil; ###p<0.001 vs ExoV C; p<0.001 vs Nil in L428 cells unexposed to CAM29.
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vesicular origin, as a result of the interaction between L428-
derived ExoV, carrying CD30, and cell membrane ADAM10
on CD30-negative MSC (Figure 5A). It is of interest that CD30
release from ExoV produced by LT4-treated L428 cells was less
efficient; also, the exposure of LT4-pretreated MSC to L428-
derived ExoV resulted in a lower sCD30 shedding (Figure 5D).
Exposure of L540 cells to either LT4 or CAM29 (10 mM for
48 h) could not only reduce sCD30 release (Figure 5E, left), but
also enhance CD30 surface expression (Figure 5F). Of note,
when endocytosis was inhibited by nocodazole, the ADAM10
inhibitors effectively reduced the expected increase in CD30
shedding due to prolonged permanence of ADAM10 and its
substrate at the level of the cell membrane (Figure 5E, right). A
similar effect was detectable using ExoV from MSC silenced for
ADAM10 (Suppl. Fig. 2C, for L540 and L428, and D for L540).
We next verified whether the two ADAM10 inhibitors could
help to maintain the anti-tumor effect of the anti-CD30 anti-
body-drug conjugate (ADC) Btx Ved. First, L428, L540 and
Figure 5. ExoV contribute to CD30 shedding and are inhibited by LT4 or CAM29. Panels A and B: L428 cells or MSC16412 (A) or latex beads-conjugated ExoV from
L428 or MSC16412 (B), were stained with the anti-CD30 mAb followed by PE-GAM (grey histograms) or PE-GAM alone (white histograms), washed and run on a
FACS. Results are shown as Log red fluorescence intensity (a.u.) vs number of cells. Panel C: sCD30 (pg/ml/105 cells) in the SN of L428 cells cultured for 48 h
without (Nil) or with ExoV (30 mg) from MSC16412 untreated (ExoV C) or treated with 10 mM LT4 (ExoV LT4) or 10 mM CAM29 (ExoV CAM29), as indicated.
Some samples were prepared using L428 cells exposed for 24 h to 10 mM LT4 (as indicated in the left histogram), before addition of MSC-derived ExoV.
p<0.05 ExoV C vs Nil; #p<0.05 ExoV LT4 vs ExoV C. Panel D: sCD30 (pg/ml/105 cells) in the SN of MSC16412 before (Nil) or after the addition of ExoV (50 or
100 mg for 48 h) from L428 untreated or pretreated with 10 mM LT4, as indicated. In some samples MSC16412 were exposed for 24 h to 10 mM LT4, as indi-
cated, before addition of MSC-derived ExoV. p<0.01 vs Nil; p<0.001 vs ExoV C matched samples; ##p<0.01, ###p<0.001 vs matched samples without LT4.
Panel E: sCD30 content (pg/ml/105 cells) in the SN of L540 cells cultured for 48 h without (Nil) or with 10 mM LT4 or 10 mM CAM29, pretreated or not with
nocodazole (Nz), as indicated. Left: p<0.05, p<0.01 vs Nil. Right: p<0.05 Nz vs Nil; p<0.01 LT4/CAM29 vs Nil: #p<0.05 NzCLT4 vs LT4;p<0.05
NzCLT4 vs Nz;p<0.01 NzCCAM29 vs Nz. Panel F: L540 cells were incubated with LT4 or CAM29 (10 mM, black histograms), as indicated, washed and stained
with the anti-CD30 mAb followed by PE-GAM (grey histograms) or PE-GAM alone (white histograms), washed and run on a FACS. Results are shown as Log
red fluorescence intensity (a.u.) vs number of cells.
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KMH2 cell lines were exposed to serial dilution of BtxVed (10
to 0.01 mg/ml) and the variation in the intracellular ATP con-
tent, as a parameter of cell viability, was evaluated at 72 h and
96 h. Suppl. Fig. 3A shows that L540 was the most sensitive cell
type to BtxVed, with a reduction of ATP content detectable
with a lower drug concentration (>50% at 1 mg/ml after 72 h;
in Suppl. Fig. 3B, data are reported as number of cells/ml at the
same time points, thus indicating that the decrease in ATP
intracellular content parallels a reduction in the number of
cells). To determine whether ADAM10 inhibitors can enhance
BtxVed effect, L428, L540 and KMH2 cells were exposed for
12 h to 10 mM LT4 or CAM29 and cultured in the presence (or
absence) of BtxVed (10 to 0.01 mg/ml). As shown in Figure 6A,
both LT4 and CAM29 reduced the ATP intracellular content
by 15% in either HL cell line after 72 h of culture. Of note, the
two ADAM10 inhibitors produced an increase of about 25% in
the efficiency of BtxVed to reduce ATP content in L428 and
L540 cells (Figure 6A, central and right panels); this effect
was more evident on KMH2 cell line, where the effect of
BtxVed was almost doubled even at the lowest ADC concen-
tration (Figure 6A, left panel). Apoptosis was then evaluated
in parallel samples of HL cell lines, exposed to serial dilution
of BtxVed alone, as above, or after exposure to 10 mM LT4 or
CAM29, by staining with annexin V (AV) and propidium
iodide (PI), followed by FACS analysis. Apoptotic cells were
identified as AVCPIC and AVCPI¡, while necrotic cells as
AV¡ PIC. LT4 was able to increase significantly the pro-apo-
ptotic effect of BtxVed at low doses (0.1 or 1 mg/ml) on
KMH2 cells (Figure 6B); on the other hand, the effect on
L428 and L540 cell lines was observed as an increase in
necrotic cells percentage upon treatment with 0.1 or 1 mg/ml
BtxVed (Figure 6C).
Figure 6. Effect of ADAM10 inhibitors on HL cell proliferation and BtxVed biological activity. Panel A: L428, KMH2 and L540 cells, either untreated or pretreated for 12 h with
10 mM LT4 or 10 mM CAM29, as indicated, were cultured for 72 h in the presence of BtxVed (10 to 0.1 mg/ml). Then intracellular ATP content was measured with the Cell-
Titer-Glo(R) Luminescent Cell Viability Assay. Results are expressed as arbitrary units of luminescence x103 and are mean § SD from 3 independent experiments.
p<0.001 vs Nil (BtxVed alone). Panel B and C: KMH2, L428 and L540 cells cultured as in panel A were stained with annexin V (AV) and propidium iodide (PI), followed by
FACS analysis. Results are expressed as percentage of apoptotic cells (panel B) identified as AVCPIC and AVCPI¡ or percentage of necrotic cells (panel C) as AV¡ PIC and
are mean with SD from 3 experiments. p<0.001 vs Nil (BtxVed alone). Panel D: cytolytic activity exerted by PBMC, isolated from 6 different donors, against KMH2, L428
and L540 cells, labeled with BATDA, at the E:T ratio of 40:1 in the presence or absence of the anti-CD30 human antibody Iratumumab (Ira, 0.1 mg/ml). After 2 h the fluores-
cence emitted by lysed cells was analyzed by the time-resolved fluorometer VICTOR2 (PerkinElmer). Results are expressed as percentage of specific release.
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In another series of experiments, we assessed the potential
ability of ADAM10 inhibitors to enhance the antibody-depen-
dent cellular cytotoxicity (ADCC) of HL cells. To this aim, we
used the human therapeutic anti-CD30 mAb Iratumumab
(Ira), also known as MDX-060,35 at the lowest dose (0.1 mg/ml)
displaying a minimum activity, based on our preliminary
results and reported data,35,36 in an ADCC assay against
KMH2, L428 and L540 HL cell lines with peripheral blood
mononuclear cells (PBMC) as effectors. As shown in
Figure 6D, pre-treatment of HL target cells with either LT4 or
CAM29 led to an increase in the Ira-induced ADCC (Nil in the
figure, cell lysis in the absence of Ira <5%, not shown). This
was evident for all PBMC donors against L540, with higher effi-
cacy of LT4 (Figure 6D: mean with Ira only 20%, with LT4
44%, with CAM29 31%); in the case of KMH2 and L428 donor
1 was more responsive to LT4-treated cells (PBMC1) and
donor 5 and 6 (PBMC5, PBMC6) to CAM29-treated HL cells
(Figure 6D).
Thus, ADAM10 specific inhibitors are able to decrease the
release of sCD30, increase its surface expression and maintain,
or increase, the biological effect of the anti-CD30 ADC BtxVed
or the human anti-CD30 Iratumumab on HL cells.
Discussion
In this paper, we show that: i) ADAM10 mature form is
released in exosome-like vesicles (ExoV) by HL cells and lymph
node mesenchymal stromal cells (MSC); ii) fluorescent
ADAM10 inhibitors localize in the endolysosomal compart-
ment in HL MSC, are released in ExoV and are in turn endocy-
tosed by bystander cells; iii) ADAM10 sheddase activity carried
by ExoV is prevented by the specific inhibitors LT4 and
CAM29; iv) in particular LT4 and CAM29 reduce CD30 shed-
ding enhancing the anti-tumor BtxVed effects and Ira-medi-
ated ADCC on Hodgkin lymphoma cells.
First, we report that the bioactive mature form of ADAM10
can be released by HL cells and lymph-node (LN) MSC in
extracellular microvesicles enriched in exosome-like particles
(ExoV, 50 to 200 nm of size); according to the literature, these
microvesicles are potentially able to spread the ADAM10 enzy-
matic activity in the microenvironment.22,23 Of note, we dem-
onstrate that specific ADAM10 inhibitors, that we reported to
block cellular ADAM10 and increase the sensitivity of HL cells
to lymphocyte-mediated killing,20,21 can also bind to exosomal
ADAM10 and interfere with its enzymatic function. In particu-
lar, we show that the fluorescent ADAM10 inhibitors CAM50
and CAM36, localize in endolysosomes in HL LN MSC and
bind to the enzyme, both at the cell membrane and in the sub-
cellular compartments. The unlabeled compound CAM29,
showing the same structure of CAM36 and CAM50 without
fluorochromes, can both prevent the recognition of ADAM10
by a specific antibody at the surface of MSC and cross-inhibit
the binding of CAM36 and CAM50. Of note, these inhibitors
can also cause the retention of ADAM10 in the endolysosomal
compartment, leading to enhanced degradation, thus reducing
its membrane localization.
Using fluorescent CAM36, we also demonstrated that
ADAM10 inhibitors are released in ExoV, either by HL cells or
MSC, and are in turn endocytosed by bystander MSC or HL
cells; this would imply that it is possible to interfere with
ADAM10 enzymatic activity conveyed by the EV exchange
between stromal and cancer cells. Indeed, in our experiments,
co-culture of MSC with ExoV released by HL cells resulted in
an increase of MICA shedding; however, ExoV collected from
HL cells that were pretreated with LT4, were not effective.
When ExoV obtained from MSC were added to HL cells, the
release of TNFa raised, unless either the ExoV-producing MSC
or the ExoV-recipient HL cells were pretreated with ADAM10
inhibitors. In this case CAM29 was much more efficient than
LT4; this is possibly due to the conserved ability of CAM29 to
inhibit also ADAM17 (Suppl. Table 1), that is reported as the
major TNFa converting enzyme.8,21 The different sensitivity
of the HL cell lines to LT4 or CAM29 (L428 being more sensi-
tive to CAM29) might also be explained on the basis of a differ-
ential expression and intracellular trafficking of tetraspannins
as transporters of ADAM10 in the different HL cell lines (this
hypothesis is currently under investigation).37 Another hypoth-
esis is that the kinetics of LT4-ExoV fusion with the plasma
membrane is more rapid than CAM29-ExoV, due the steric
hindrance of CAM29 and a possible different conformational
change of vesicular ADAM10 that favors its permanence on
the plasma membrane, thus allowing more visible inhibition.
As CD30 is a substrate for ADAM10 and also a target for
immunotherapy,19,33-36 we analyzed the effect of ExoV on CD30
shedding from HL cells and investigated the ability of ADAM10
inhibitors to counteract this process. ExoV released by MSC
could indeed enhance sCD30 shedding by HL cells and this pro-
cess was prevented by pretreating with ADAM10 inhibitors
either HL cells before co-incubation with ExoV, or MSC during
the release of ExoV. It is of interest that a dose-dependent
sCD30 increase in culture media (CM) was detected also when
ExoV obtained from HL cells were added to MSC. As ExoV
bind to the cell membrane and are internalized by MSC, sCD30
shedding is conceivably a result of the interaction between HL-
derived ExoV, carrying CD30, and ADAM10 on MSC cell-mem-
brane, in keeping with other reports.33 This is further supported
by the finding that HL-derived ExoV were much less effective
on MSC pretreated with the ADAM10 inhibitor LT4. Of note,
we also show that the two ADAM10 inhibitors, besides showing
themselves a partial inhibitory effect on HL cell proliferation,
can help to maintain and enhance the anti-tumor effect of the
anti-CD30 ADC BtxVed and the Iratumumab-mediated ADCC
of HL target cells (Figure 7).
Thus, the cross-talk occurring between stromal and cancer
cells in the HL microenvironment, due to exosome-like micro-
vesicles and ADAM10 activity, can result in the release of cyto-
kines, as TNFa, described as lymphoma growth factor,34 or
soluble molecules, such as sMICA or sCD30, that potentially
interfere with host immune response, or with ADC-based
immunotherapy.14-18,33 ADAM10 blockers can interfere with
such process, allowing the development of an anti-lymphoma
immune response and/or an efficient ADC-based or humanized
Ab-immunotherapy (Figure 7).19-21,33-36,38
Methods
Cell cultures. The HL cell line L428 or KMH2, from pleural
effusion, and L540, from bone marrow of HL patients, (DSMZ
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GmbH, Braunschweig, Germany), and the RS773 cell line
obtained from a HL lymph node (LN) were maintained in
RPMI 1640 complete medium supplemented with 10% FCS
and glutamine (2 mM).18 The LN MSC773 and MSC16412
were cultured in MEM-a (GIBCO) supplemented with 1%
Chang medium, glutamine (2 mM), 1% penicillin/streptomy-
cin. Stabilization of primary HL and MSC cultures was per-
formed as described.18,20
ADAM10 inhibitors. LT4 was synthesized as described,21
and CAM29, showing a IC50 selective for ADAM10
(Supplemental Data and Suppl.Table 1), or CAM29 conjugated
with cyanine 5.5 (Cy5.5, CAM36) or with fluorescein-isothiocy-
anate (FITC, CAM50), were newly synthesized.30 As reported
in our previous publication,21 LT4 is a sulfonamido-based
hydroxamate that inhibits ADAM10 by interacting with its cat-
alytic domain by chelating the zinc ion, critical for both sub-
strate binding and cleavage. CAM29 is its PEGylated analogue
used to prepare the fluorescent probes and the CAM49 gold
nanoprobe prepared by conjugating multivalent gold nanopar-
ticles with CAM29.30 Compound ST178, a Cy5.5-N-isopropyl
Figure 7. Proposed model for the role of ADAM10 inhibitors in maintaining BtxVed and Iratumumab biological effect. Panel A: HL malignant cells, expressing CD30, in the
lymphoid tissue are in contact with MSC. Shedding of sCD30 as a consequence of ADAM10 enzymatic activity, either present at the surface of HL or MSC, or carried by
ExoV, leads to decreased membrane-associated CD30 expression and impairment of BtxVed or Iratumumab (Ira) binding to HL cells. Panel B: LT4 and CAM29, either inside
HL cells or MSC, or carried by ExoV, would inhibit cellular or exosomal ADAM10, reducing sCD30 release, increasing CD30 surface expression and allowing BtxVed or Ira
recognition of HL cells and anti-tumor biological effect.
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amide unable to bind ADAM10, was used as a negative control
for the fluorescent probes.
The ADAM10 inhibitors used on the different HL cell lines,
or on isolated MSC, at 2.5 up to 10 mM concentration for 48,
72 and 96 h (and the solvent DMSO at the same dilutions and
time points) did not exert any toxic effect, as assessed by evalu-
ating the mitochondrial potential upon staining with the dual
emission fluorescent probe JC-1 (Molecular Probes, Life Tech-
nologies Italia, Monza) and did not induce directly necrosis or
apoptosis, evaluated by annexin V/ PI staining (not shown).
MMP and ADAMs inhibition assays were performed as
described (Suppl. Data).39,40
Small interfering RNA (siRNA) transfection and real-time RT-
PCR. ON-TARGET plus SMART pool for human ADAM10
(100 nM, Dharmacon CarloErba, Milan, Italy) was used to
knockdown the expression of ADAM10; siCONTROL non-
targeting (NT) siRNA pool (Dharmacon) was used as negative
control. MSC773 (2.5 £ 105) were transfected in serum-free
Opti-MEM medium (Gibco, Life Technologies) with Lipofect-
amine 2000 (Invitrogen, Life Technologies) following the manu-
facturer’s instructions. ADAM10 expression by western blot was
analyzed 72 h after transfection in MSC773 and in the ExoV
released by the same cells, purified as described below.
MSC773 cells, untreated or silenced, were then stained with
the anti-ADAM10 mAb, followed by isotype-specific APC-
GAM and run on a CyAn ADP Analyzer. In some experiments,
ExoV from MSC773, untreated or silenced with ADAM10
siRNA or with NT siRNA pool were added to L540 or L428
cells (10 mg/105 cells) for 24 h, then SN were collected for
sCD30 ELISA and cells were stained with the anti-CD30 mAb,
followed by APC-GAM, and run on a CyAn ADP Analyzer.
Total RNA was isolated from controls and treated cells using
the RNeasy Mini kit (Qiagen Italia, Milan) according to the
manufacturer’s instructions. mRNA expression was analyzed
by quantitative real-time reverse transcription-PCR, by using
the following specific primers: ADAM10 sense 50-ATG TTT
TCA TGC GGT GCA GAT and antisense 50-GTA ATA CTG
CCC ACC AAT GAG C; 18 S sense 50-ACACGGACAGGATT-
GACAGATT and antisense 50-AGACAAATCGCTCCAC-
CAACTA. cDNA amplification and relative expression values
were obtained as described.41
ELISA for sMICA, TNFa and sCD30. Conditioned culture
media (CM) were collected from cell cultures (either MSC or
HL cell lines), untreated or after 48 h exposure to the ADAM10
inhibitors (LT4, CAM29, 10 mM). In some experiments, the
release of ADAM10 substrates by MSC773 cells, untreated
(WT), or silenced with ADAM10 siRNA, or with NT siRNA
pool for 48 h was measured in the CM by ELISA.
The anti-MICA mAbs AMO1 and BAMO3 were from
Immatics Biotechnologies (Tubingen, Germany) and the ELISA
detection kit for sCD30 (Human CD30 Picokine ELISA kit)
from Boster Bio (TebuBio, Milan, Italy). Anti-mouse IgG2 a
HRP was from Southern Biotechnology (Birmingham, AL).
Plates were developed with 3,30,5,50-tetramethylbenzidine
(Sigma-Aldrich, Milan, Italy) and read at a OD450nm. Results
are expressed as pg/ml and referred to a standard curve
obtained with the MICA/Fc chimera (R&D System) or the stan-
dard CD30 contained in the specific kit. TNFa was measured
after treatment for 1 h of SN with 1 N HCl followed by 1 N
NaOH with a TNFa specific kit (PeproTech, London, UK).
Results normalized to a standard curve are expressed as pg/ml.
Cell proliferation and evaluation of apoptosis/necrosis. Cell pro-
liferation was assessed at 72 or 96 h, upon treatment of KMH2,
L428 or L540 cell lines with LT4 or CAM29 (10 mM) or with
BtxVed (10 to 0.01 mg/ml), provided by the Pharmacy Service of
our Institute, by measuring the intracellular ATP content with the
CellTiter-Glo(R) Luminescent Cell Viability Assay (Promega Ita-
lia, Milan, Italy) according to the manufacturer’s instruction. In
some experiments, HL cell lines were exposed for 12 h to 10 mM
LT4 or 10 mM CAM29, prior to BtxVed treatment. Results are
expressed as arbitrary units (a.u.) of luminescence. Parallel sam-
ples were used for cell count evaluation by FACS. Apoptosis was
evaluated in HL cell lines, treated with serial dilution of BtxVed
alone, as above, or after 12 h exposure to 10 mM LT4 or CAM29,
by staining intact cells with annexin-V (AV) and propidium
iodide (PI), (Sigma-Aldrich), followed by FACS analysis. Necrotic
cells were identified as AV¡ PIC, apoptotic cells as AVCPIC and
AVCPI¡, living cells as AV¡PI¡.
ADCC assay. The DELFIA EuTDA cytotoxicity reagents have
been used (PerkinElmer, Wellesley, MA, USA). KMH2, L428 or
L540 cell lines, untreated or exposed for 12 h to 10 mM LT4 or
CAM29, were labelled with bis-acetoxymethyl 2,2 0,6 0,2“-terpyri-
dine-6,6”-dicarboxylate (BATDA) for 20 min at 37C, washed and
co-incubated in 96-well round bottom plates with PBMC, isolated
from 6 different buffy coats, at the E:T ratio of 40:1 in the presence
or absence of the anti-CD30 human antibody Iratumumab (Ira,
Creative Biolabs, Shirley, NY, USA), at the lowest dose (0.1mg/ml)
displaying a minimum activity, based on our preliminary results
and reported data.35,36 After 2 h, 20 ml of supernatant from each
well were transferred to flat-bottomed plates and 200 ml of Euro-
pium solution was added. The fluorescence emitted by the binding
of Europium with the ligand TDA was analyzed by the time-
resolved fluorometer VICTOR2 (PerkinElmer). The percentage of
specific release was calculated applying the following formula:
experimental release (counts)-spontaneous release (counts)/maxi-
mum release (counts)-spontaneous release (counts). Maximum
and spontaneous release were calculated according to themanufac-
ture’s instruction.
Subcellular fractionation. Lysosomal, endosomal and mem-
brane fractions were isolated by differential centrifugation follow-
ing published procedures42,43 with slight modifications (see
Supplemental Data). Briefly, cell pellets obtained from 107
MSC16142 or MSC773 were washed in PBS, suspended in 1 ml
homogenization buffer (250 mM sucrose, 0.5 mM EGTA), 20 mM
Hepes-KOH (pH7) and passed sequentially through 21G1/2 and
25G needles. The homogenate was centrifuged 10 min at 1000 xg
(nuclear fraction). Post-nuclear supernatants (cells) were centri-
fuged in an Eppendorf 5417 R refrigerated minicentrifuge at
8000 xg for 20 min (L: lysosome-enriched fraction); supernatants
were further ultracentrifuged in TL-100 ultracentrifuge 10 min at
50000 xg (E: endosome-enriched fraction), 90 min at 100000 xg
(M: membrane-enriched fraction) and the last recovered as super-
natant (SN). All fractions were suspended in RIPA buffer with pro-
tease inhibitors (Sigma-Aldrich), stored at¡20C, or processed for
western blot analysis. Protein content was assessed by the Lowry
DC protein Assay (BioRad,Wadfirt, UK).
Western Blot. Total cell lysates were prepared in RIPA buffer
supplemented with 1 mM orthovanadate. Protein quantification
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was performed with the DC Protein Assay (Bio-Rad). Samples
(10–20 mg of proteins) of either cell lysates or subcellular frac-
tions, were resolved on 4–20% gradient SDS-polyacrylamide
Tris-Glycine gels and transferred on PVDF membranes (GE-
Healthcare, Milan, Italy). Western Blot analysis was performed
with the following antibodies: mouse monoclonal (mAb) anti-
ADAM10 ectodomain (non-reducing conditions) clone 163003,
R&D Systems (Milano, Italy); rabbit polyclonal anti ADAM10
ab1997, Abcam (Cambridge, UK); anti-MICA/B mAb (BAMO1,
BAMOMAB GmbH, Gr€afelfing, Germany); anti-CD81 mAb
clone 5A6, or CD63 clone H5C6 (BioLegend, San Diego, CA,
USA). For the identification of subcellular fractions by specific
markers the following antibodies were used: anti-cathepsin-D
(Calbiochem, Merck Millipore, Vimodrone, Milan, Italy); anti-
EEA1 (mAb BD Biosciences, Milano, Italy); anti-lysosome-asso-
ciated membrane glycoprotein-1 (LAMP-1) 1D4B (Developmen-
tal Studies Hybridoma Bank, Iowa City, Iowa) anti-Rab7 (B-3,
Santa Cruz Biotechnology, Heilderberg, Germany); secondary
anti-mouse and anti-rabbit horseradish peroxidase (HRP)-labeled
antibodies were from Cell Signaling Technology (Danvers, MA).
ImmobilonTM Western Chemiluminescent HRP Substrate (ECL)
was from Merck Millipore.
Immunohistochemistry. Paraffin-embedded samples from 10
HL patients, obtained from the Unit of Pathology, IRCCS Policli-
nico San Martino, Genoa, under conventional diagnostic proce-
dures, provided informed consent and approval by the institutional
ethical committee (IRB approval 0026910/07, renewal 03/2009,
and 14/09/15). were analyzed (4 are shown) for the expression in
situ of ADAM10, CD30 and transglutaminase (TG)II. Immunohis-
tochemistry was performed on 6-mm-thin sections, treated with
Peroxo-Blok (Novex, Life Technologies) to quench endogenous
peroxidase, followed by Ultra Blok reagent (Ultravision Detection
System, BioOptica, Milan Italy). The following antibodies were
added: polyclonal rabbit anti-ADAM10 antiserum (1:100, Abcam),
anti-CD30mAb (2mg/mL), polyclonal rabbit anti-TGII antiserum
(1:100, Thermo Scientific) and an isotypic unrelated antibody
was used as negative control (Dako Cytomation). Biotinylated
goat anti-rabbit or goat anti-mouse antiserum (BioOptica) was
then added, followed by HRP-conjugated avidin (Thermo Scien-
tific) and the reaction developed using 3,30-diaminobenzidine
(DAB) as chromogen. Slides were counterstained with hematoxy-
lin, cover-slipped with Eukitt (Bio Optica), and analyzed under a
Leica DM MB2 microscope equipped with a charged coupled
device (CCD) camera (OlympusDP70with a 20x or 40x objective).
ExoV isolation from MSC or HL cell lines and HL patients’ sera.
L428 or L540 HL cell lines or MSC16412 and MSC773 were cul-
tured in serum-free medium for 48 h; then ExoV were isolated fol-
lowing published procedures,44 with slight modifications described
in detail in the Supplemental Data section. Briefly, the conditioned
medium (CM) from T175 flasks containing 90% confluent MSC
(2.8 £ 107) or from HL cells (4 £ 107), was centrifuged at 300 xg
for 15 min and 2000 xg for 20 min to remove live and dead cells,
and cell debries, respectively. The supernatant was concentrated
10-fold and dialyzed against PBS with Amicon Ultra-4 or Ultra-
15 devices (NMWL 100 kDa) (Merck Millipore) at 3000 xg, cen-
trifuged at 20000 xg for 20 min and at 100000 xg for 120 min in a
TL-100 Ultracentrifuge equipped with TLA-100.3 rotor (Beckman
Coulter, Milan, Italy). The pellet containing purified ExoV was
washed with PBS by centrifugation at 100000 xg, to remove
contaminating protein aggregates, and suspended in RIPA buffer
with protease inhibitors for western blot, or in PBS for cell cultures
or transmission electron microscopy. ExoV, purified from 6 HL
patients’ sera (IRB as above), following the same procedure, were
subjected to WB for ADAM10 and CD81 as described above. Pro-
tein concentration was measured by the DC Protein assay. ExoV
size and concentration was verified by as described in Supplemen-
tal Methods.
Latex beads conjugation of ExoV and FACS analysis. Aldehyde
sulfate latex beads (Life Technologies) were washed with 1 mM
MES buffer pH 6.0, collected by centrifugation (3000 xg, 20 min),
mixed (3 £ 105 bead/sample) with 15, 30 or 60 mg of ExoV, puri-
fied from MSC 16412 of L428 cells and incubated overnight at RT
in a vertical tube rotator. The reaction was stopped with PBS-Gly-
cine (final concentration 100 mM) and beads were washed with
PBS, 3% FCS, 0.01% NaN3, incubated with anti-ADAM10 anti-
body for 30 min at 4C, washed and stained with APC-conjugated
secondary antibody. 100000 beads were analyzed on a CyAn ADP
Analyzer (Beckman Coulter, Milano, Italy) set according to Thery
et al. (Suppl. Data and Suppl. Fig. 1).42 In other experiments, 2.5£
104 MSC16412 or MSC773 were pre-incubated with CAM29
(10 mM or 1 mM) 20 min at RT, washed, stained with the anti-
ADAM10 ectodomain mAb followed by APC-conjugated goat
anti-mouse (GAM) anti-serum and run on a CyAn ADP Analyzer
(Beckman Coulter). Results are reported as Log red fluorescence
intensity (arbitrary units, a.u.) vs cell number. In some experiments
ExoV, obtained from MSC16412 or MSC773 exposed to CAM36
for 24 h, were coupled to latex beads and analyzed by a CyAn ADP
Analyzer (see Supplemental Data). Other ExoV samples, and the
relative producing L428, L540 or MSC16412 cells, were stained
with the anti-CD30 mAb followed by PE-GAM (grey histograms)
or PE-GAMalone (white histograms), and analyzed by FACS.
Co-culture of MSC or HL cells with ExoV. For functional
experiments, 10, 15, 30 or 60 mg of ExoV obtained from HL cell
lines L428 or L540, either untreated or exposed to 10 mM LT4
or CAM29 for 24 h, were added to sub-confluent MSC773 or
MSC16412 seeded in flat bottom 96 w plates and placed at 37C
in a 5%CO2 incubator; in some samples, MSC773 or MSC16412
were exposed to 10 mM LT4 or CAM29 for 24 h before adding
L428 or L540-derived ExoV. In other experiments, 30 mg of
ExoV produced by MSC773 or MSC16412, either untreated or
pretreated for 24 h with 10 mM LT4 or CAM29, were added to
L428 or L540 cells (106/ml) in 96 w or 24 w plates and incubated
at 37C; in some samples, L428 or L540 cells were exposed to
10 mM LT4 or CAM29 for 24 h before addition of MSC-derived
ExoV. After 48 h of culture, CM were collected, centrifuged at
100000 xg for 90 min to remove ExoV and analyzed for sMICA,
sCD30 or TNFa by ELISA. Another series of experiments were
performed with ExoV, obtained from MSC16412 exposed to
CAM36, or the unrelated Cy5.5 compound ST178, for 24 h;
these ExoV were either conjugated with latex beads (see below)
or added (15 mg/105cells) for 2 h to L428 cells previously seeded
on 0.2 mm thin round glass slides and cultured for 24 h. In
turn, ExoV from CAM36-treated (24 h) L428 were added to
MSC16412 previously seeded on glass slides as above; then all
samples were analyzed by either FACS analysis, after detachment
from the slides, or confocal microscopy (see below).
Confocal Microscopy. 2.5 £ 104 MSC (either MSC16412 or
MSC773) seeded on 0.2 mm thin round glass slides were
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incubated for 24 h with Rab5GFP (CellLight Reagents BacMam
2.0, Thermo Fisher, 2 mL) or 1 h with LysoTracker DND99
(Thermo Fisher, 50 nM). After extensive washes, slides were
stained with CAM36 or CAM50 at 5 mM for 60 min at RT.
Some samples were treated with 10 mM nocodazole (Sigma-
Aldrich) for 1 h at 37C prior to exposure to CAM36. In other
experiments, L428 or MSC16412, labelled with either Rab5-GFP
or LysoTracker DND99, were exposed to CAM36-ExoV (15mg/
105 cells) as described above and incubated 4 h (to optimize
images) at 37C before performing confocal microscopy. Samples
were then analyzed by FV500 (FluoView confocal Laser Scan-
ning Microscope System, Olympus Europe GMBH, Hamburg,
Germany) equipped with an Argon laser to excite carboxyfluo-
scein and a He-Neon red laser at 633 nm to excite cyanine 5
dye associated to a IX81 motorized microscope (Olympus). Sam-
ples were observed with PlanApo 40x NA1.00 or 60x NA1.40 oil
objectives and data analyzed with FluoView 4.3b computer pro-
gram (Olympus). Each image has been taken in sequence mode
to avoid cross-contribution of each fluorochrome. Results are
shown as bright field or pseudocolor images.
Transmission electron microscopy. ExoV-containing pellet
(50–100mg of protein) was resuspended in 50 to 100 ml of 2%
PFA and 5ml were deposited on Formvar-carbon coated EM grids
for 20 min, then transferred to a 50-ml drop of 1% glutaraldehyde
for 5 min. Grids were washed 8 times with 100ml drop of distilled
water for 2 min and transferred to a 50ml drop of uranyl-oxalate
solution, pH 7, for 5 min. Samples were then contrasted in a solu-
tion of uranyl oxalate, pH 7, embedded in a mixture of 4% uranyl
acetate and 2% methyl cellulose in a ratio of 100ml/900ml, trans-
ferred to a 50-ml drop of methyl cellulose-UA for 10 min on ice
and air dried. ExoV were observed under a transmission electronic
microscope Zeiss Leo EM 900 at 80 kV. For TEM analysis of
MSC16412 exposed to gold-conjugated CAM29 (CAM49) over-
night at 2.5 mM concentration, cells were processed as described30
(see Supplemental Methods).
Statistical analysis. Data are presented as mean § SE. The
values have been tested for Gaussian distribution by the D’Ag-
ostino-Pearson test. Statistical analysis was performed, using
two-tailed unpaired Student’s t test or One way ANOVA with
Tuckey’s multicomparison test by the GraphPad Prism 5 Ver-
sion 5.03 computer software. The cut-off value of significance
is indicated in each figure legend.
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